Angela Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Angela Sun has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Irene J. Chang
Division of Medical Genetics, Department of Pediatrics University of California, San Francisco (UCSF) San Francisco California USA
3 shared publications - Christina Lam
Norcliffe Foundation Center for Integrative Brain Research, Seattle Children's Research Institute , Seattle, WA
2 shared publications Ian A. Glass
Department of Medical Genetics, University of Washington Medical Center, Seattle, Washington
2 shared publicationsMichael J. Goldberg
Department of Orthopaedics and Sports Medicine, University of Washington School of Medicine, Seattle, Wash
2 shared publicationsSusan Hale
Department of Orthopaedics and Sports Medicine, University of Washington School of Medicine, Seattle, Wash
2 shared publicationsAndy Dang
1 shared publication
Latest Publications
- 8 February 2023
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 138 (2) , 126
Mucopolysaccharidosis type VII treated in the first year of life: A case report
- 8 February 2023
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 138 (2) , 126
Mucopolysaccharidosis type VII treated in the first year of life: A case report
- 3 February 2022
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 135 (2) , S117-S118
A rapid and non-invasive proteomic analysis using DBS and buccal swab for multiplexed second-tier screening of Pompe disease and Hurler syndrome
- 3 February 2022
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 135 (2) , S117-S118
A rapid and non-invasive proteomic analysis using DBS and buccal swab for multiplexed second-tier screening of Pompe disease and Hurler syndrome
- 19 April 2021
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 185 (9) , 2649
A lasting imprint
- 19 April 2021
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 185 (9) , 2649
A lasting imprint
- Open Access
- 5 June 2020
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 182 (7) , 1576-1591
Activating variants in PDGFRB result in a spectrum of disorders responsive to imatinib monotherapy
More than 50 individuals with activating variants in the receptor tyrosine kinase PDGFRB have been reported, separated based on clinical features into solitary myofibromas, infantile myofibromatosis, Penttinen syndrome with premature aging and osteopenia, Kosaki overgrowth syndrome, and fusiform aneurysms. Despite their descriptions as distinct clinical entities, review of previous reports demonstrates substantial phenotypic overlap. We present a case series of 12 patients with activating variants in PDGFRB and review of the literature. We describe five patients with PDGFRB activating variants whose clinical features overlap multiple diagnostic entities. Seven additional patients from a large family had variable expressivity and late‐onset disease, including adult onset features and two individuals with sudden death. Three patients were treated with imatinib and had robust and rapid response, including the first two reported infants with multicentric myofibromas treated with imatinib monotherapy and one with a recurrent p.Val665Ala (Penttinen) variant. Along with previously reported individuals, our cohort suggests infants and young children had few abnormal features, while older individuals had multiple additional features, several of which appeared to worsen with advancing age. Our analysis supports a diagnostic entity of a spectrum disorders due to activating variants in PDGFRB. Differences in reported phenotypes can be dramatic and correlate with advancing age, genotype, and to mosaicism in some individuals.
- 5 June 2020
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 182 (7) , 1576-1591
Open AccessActivating variants in PDGFRB result in a spectrum of disorders responsive to imatinib monotherapy
More than 50 individuals with activating variants in the receptor tyrosine kinase PDGFRB have been reported, separated based on clinical features into solitary myofibromas, infantile myofibromatosis, Penttinen syndrome with premature aging and osteopenia, Kosaki overgrowth syndrome, and fusiform aneurysms. Despite their descriptions as distinct clinical entities, review of previous reports demonstrates substantial phenotypic overlap. We present a case series of 12 patients with activating variants in PDGFRB and review of the literature. We describe five patients with PDGFRB activating variants whose clinical features overlap multiple diagnostic entities. Seven additional patients from a large family had variable expressivity and late‐onset disease, including adult onset features and two individuals with sudden death. Three patients were treated with imatinib and had robust and rapid response, including the first two reported infants with multicentric myofibromas treated with imatinib monotherapy and one with a recurrent p.Val665Ala (Penttinen) variant. Along with previously reported individuals, our cohort suggests infants and young children had few abnormal features, while older individuals had multiple additional features, several of which appeared to worsen with advancing age. Our analysis supports a diagnostic entity of a spectrum disorders due to activating variants in PDGFRB. Differences in reported phenotypes can be dramatic and correlate with advancing age, genotype, and to mosaicism in some individuals.
- Top Cited Papers
- 1 December 2018
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 6 (24) , 476.
Lysosomal storage disease overview
The lysosomal storage diseases (LSDs) are a group of inherited metabolic disorders that are caused for the most part by enzyme deficiencies within the lysosome resulting in accumulation of undegraded substrate. This storage process leads to a broad spectrum of clinical manifestations depending on the specific substrate and site of accumulation. Examples of LSDs include the mucopolysaccharidoses, mucolipidoses, oligosaccharidoses, Pompe disease, Gaucher disease, Fabry disease, the Niemann-Pick disorders, and neuronal ceroid lipofuscinoses. This review summarizes the main clinical features, diagnosis, and management of LSDs with an emphasis on those for which treatment is available.
- 1 December 2018
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 6 (24) , 476.
Top Cited PapersLysosomal storage disease overview
The lysosomal storage diseases (LSDs) are a group of inherited metabolic disorders that are caused for the most part by enzyme deficiencies within the lysosome resulting in accumulation of undegraded substrate. This storage process leads to a broad spectrum of clinical manifestations depending on the specific substrate and site of accumulation. Examples of LSDs include the mucopolysaccharidoses, mucolipidoses, oligosaccharidoses, Pompe disease, Gaucher disease, Fabry disease, the Niemann-Pick disorders, and neuronal ceroid lipofuscinoses. This review summarizes the main clinical features, diagnosis, and management of LSDs with an emphasis on those for which treatment is available.
- 1 September 2018
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 6 (5) , 1749-1751
Immune modulation in a patient with Morquio syndrome treated with enzyme replacement therapy
- 1 September 2018
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 6 (5) , 1749-1751
Immune modulation in a patient with Morquio syndrome treated with enzyme replacement therapy
- 16 July 2018
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 176 (7) , 1675-1679
Novel phenotype of achondroplasia due to biallelicFGFR3pathogenic variants
Pathogenic variants in the fibroblast growth factor receptor 3 (FGFR3) gene are responsible for a broad spectrum of skeletal dysplasias, including achondroplasia (ACH). The classic phenotype of ACH is caused by two highly prevalent mutations, c.1138G > A and c.1138G > C (p.Gly380Arg). In the homozygous state, these variant results in a severe skeletal dysplasia, neurologic deficits, and early demise from respiratory insufficiency. Although homozygous biallelic mutations have been reported in patients with ACH in combination with hypochondroplasia or other dominant skeletal dysplasias, thus far, no cases of heterozygous biallelic pathogenic ACH‐related variants inFGFR3have been reported. We describe a novel phenotype of an infant with two ACH‐related mutations inFGFR3, p.Gly380Arg and p.Ser344Cys. Discordant features from classic ACH include atypical radiographic findings, severe obstructive sleep apnea, and focal, migrating seizures. We also report the long‐term clinical course of her father, who harbors the p.Ser344Cys mutation that has only been reported once previously in a Japanese patient. The phenotype of heterozygous biallelic mutations inFGFR3associated with ACH is variable, underscoring the importance of recognition and accurate diagnosis to ensure appropriate management.
- 16 July 2018
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 176 (7) , 1675-1679
Novel phenotype of achondroplasia due to biallelicFGFR3pathogenic variants
Pathogenic variants in the fibroblast growth factor receptor 3 (FGFR3) gene are responsible for a broad spectrum of skeletal dysplasias, including achondroplasia (ACH). The classic phenotype of ACH is caused by two highly prevalent mutations, c.1138G > A and c.1138G > C (p.Gly380Arg). In the homozygous state, these variant results in a severe skeletal dysplasia, neurologic deficits, and early demise from respiratory insufficiency. Although homozygous biallelic mutations have been reported in patients with ACH in combination with hypochondroplasia or other dominant skeletal dysplasias, thus far, no cases of heterozygous biallelic pathogenic ACH‐related variants inFGFR3have been reported. We describe a novel phenotype of an infant with two ACH‐related mutations inFGFR3, p.Gly380Arg and p.Ser344Cys. Discordant features from classic ACH include atypical radiographic findings, severe obstructive sleep apnea, and focal, migrating seizures. We also report the long‐term clinical course of her father, who harbors the p.Ser344Cys mutation that has only been reported once previously in a Japanese patient. The phenotype of heterozygous biallelic mutations inFGFR3associated with ACH is variable, underscoring the importance of recognition and accurate diagnosis to ensure appropriate management.
- 1 July 2017
- Published by Elsevier in Neuromuscular Disorders
- Vol. 27 (7) , 616-618
Novel truncating variant in DNA2-related congenital onset myopathy and ptosis suggests genotype–phenotype correlation
- 1 July 2017
- Published by Elsevier in Neuromuscular Disorders
- Vol. 27 (7) , 616-618
Novel truncating variant in DNA2-related congenital onset myopathy and ptosis suggests genotype–phenotype correlation
- 12 May 2016
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 170 (8) , 2181-2185
Whole exome sequencing identifies the first STRADA point mutation in a patient with polyhydramnios, megalencephaly, and symptomatic epilepsy syndrome (PMSE)
Polyhydramnios, megalencephaly, and symptomatic epilepsy syndrome (PMSE) is an ultra rare neurodevelopmental disorder characterized by severe, infantile‐onset intractable epilepsy, neurocognitive delay, macrocephaly, and craniofacial dysmorphism. The molecular diagnosis of this condition has thus far only been made in 16 Old Order Mennonite patients carrying a homozygous 7 kb founder deletion of exons 9–13 of STRADA. We performed clinical whole exome sequencing (WES) on a 4‐year‐old Indian male with global developmental delay, history of failure to thrive, infantile spasms, repetitive behaviors, hypotonia, low muscle mass, marked joint laxity, and dysmorphic facial features including tall forehead, long face, arched eyebrows, small chin, wide mouth, and tented upper lip. A homozygous single nucleotide duplication, c.842dupA (p.D281fs), in exon 10 of STRADA was identified. Sanger sequencing confirmed the mutation in the individual and identified both parents as carriers. In light of the molecular discoveries, the patient's clinical phenotype was considered to be a good fit for PMSE. We identified for the first time a homozygous point mutation in STRADA causing PMSE. Additional bi‐allelic mutations related to PMSE thus far have not been observed in Baylor ∼6,000 consecutive clinical WES cases, supporting the rarity of this disorder. Our findings may have treatment implications for the patient since previous studies have shown rapamycin as a potential therapeutic agent for the seizures and cognitive problems in PMSE patients.
- 12 May 2016
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 170 (8) , 2181-2185
Whole exome sequencing identifies the first STRADA point mutation in a patient with polyhydramnios, megalencephaly, and symptomatic epilepsy syndrome (PMSE)
Polyhydramnios, megalencephaly, and symptomatic epilepsy syndrome (PMSE) is an ultra rare neurodevelopmental disorder characterized by severe, infantile‐onset intractable epilepsy, neurocognitive delay, macrocephaly, and craniofacial dysmorphism. The molecular diagnosis of this condition has thus far only been made in 16 Old Order Mennonite patients carrying a homozygous 7 kb founder deletion of exons 9–13 of STRADA. We performed clinical whole exome sequencing (WES) on a 4‐year‐old Indian male with global developmental delay, history of failure to thrive, infantile spasms, repetitive behaviors, hypotonia, low muscle mass, marked joint laxity, and dysmorphic facial features including tall forehead, long face, arched eyebrows, small chin, wide mouth, and tented upper lip. A homozygous single nucleotide duplication, c.842dupA (p.D281fs), in exon 10 of STRADA was identified. Sanger sequencing confirmed the mutation in the individual and identified both parents as carriers. In light of the molecular discoveries, the patient's clinical phenotype was considered to be a good fit for PMSE. We identified for the first time a homozygous point mutation in STRADA causing PMSE. Additional bi‐allelic mutations related to PMSE thus far have not been observed in Baylor ∼6,000 consecutive clinical WES cases, supporting the rarity of this disorder. Our findings may have treatment implications for the patient since previous studies have shown rapamycin as a potential therapeutic agent for the seizures and cognitive problems in PMSE patients.